Clinical Trials on Vitamin D Deficiency Disease in Korea, Republic of

Total 619 results

VaxGen

Completed

Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection

HIV Infections | HIV Seronegativity

United States, Canada, Netherlands, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) (ASSURE)

Infection, Human Immunodeficiency Virus

United States, Puerto Rico
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

HIV Infections | HIV-1

United States, France, United Kingdom, China, Belgium, Germany, Spain, Chile, Mexico, Portugal, Costa Rica, Panama, South Africa, Canada, Brazil, Puerto Rico, Russian Federation, Thailand, Australia, India
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States, United Kingdom, France, Spain, Germany, Belgium, Puerto Rico, Canada, Italy, Austria, Australia, Portugal
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

Canada, United States, Puerto Rico, Thailand, Australia, France, Belgium, United Kingdom, Germany, Italy, Austria, Mexico, Portugal, Switzerland, Denmark, Netherlands, Sweden
Glaxo Wellcome

Completed

A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine

HIV Infections | Toxoplasmosis, Cerebral

United States, Canada
ViiV Healthcare

Completed

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Puerto Rico, Costa Rica, Panama
GlaxoSmithKline

Completed

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Mexico
ViiV Healthcare

Completed

Expanded Access Program for Maraviroc At Multiple Centers

HIV Infections

Canada, United States, Spain, Switzerland, Malaysia, France, Italy, Portugal, Puerto Rico, Mexico, Australia, Ireland, Romania, Greece, United Kingdom, Argentina, Austria, Belgium, Chile, Costa Rica, Dominican Republic, Germany, Hong... and more
Shaman Pharmaceuticals

Completed

Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)

HIV Infections | Herpes Simplex

United States, Puerto Rico
Boehringer Ingelheim

Completed

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

HIV Infections

Netherlands, Germany, Canada, United States, France, United Kingdom, Switzerland, Denmark, Australia, Greece, Portugal, Belgium, Italy
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 2)

HIV Infections

Netherlands, United States, Italy, Spain, United Kingdom, France, Germany, Australia, Switzerland, Belgium, Canada, Poland, Sweden
ViiV Healthcare
GlaxoSmithKline

Completed

Fosamprenavir Versus Other Protease Inhibitors

Infection, Human Immunodeficiency Virus I

United States, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Hepatitis C | Human Immunodeficiency Virus

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

Canada, Switzerland, United States, France, Spain, Germany, Belgium, Austria, Italy, United Kingdom, Puerto Rico, Portugal
Boehringer Ingelheim

Completed

VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients

HIV Infections

United States, Argentina, Australia, Belgium, Botswana, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russian Federation, South Africa, Spain, Switzerland, United Kingdom
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
Gilead Sciences

Completed

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV-1

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)

HIV Infections

United Kingdom, Argentina, Switzerland, France, Brazil, United States, Estonia, Spain, Australia, Peru, Austria, Belgium, Canada, Germany, Ireland, Israel, Italy, Japan, Lithuania, Luxembourg, Martinique, New Zealand, Norway, Poland, Puerto... and more
Avexa

Terminated

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

HIV Infections

Canada, United States, Australia, United Kingdom, Thailand, Germany, Italy, Israel, Belgium, Puerto Rico, Peru
ViiV Healthcare

Completed

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Infection, Human Immunodeficiency Virus

United States, Spain, Peru, Romania, Colombia, South Africa, Germany, Russian Federation, Argentina, Mexico
Tibotec Pharmaceuticals, Ireland

Completed

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, China, Germany, South Africa, Russian Federation, Argentina, Brazil, Puerto Rico, Austria, Thailand, Mexico, Uganda
Merck Sharp & Dohme LLC

Active, not recruiting

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

HIV Infection

United States, Australia, Austria, Canada, Finland, France, Germany, Italy, Japan, Puerto Rico, Spain
ViiV Healthcare
GlaxoSmithKline

Completed

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

HIV Infections

United States, Germany, Spain, France, Australia, Canada, Belgium, Netherlands, United Kingdom, Japan
Gilead Sciences

Completed

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

HIV Infection

Canada, Germany, United States, Spain, France, Australia, Puerto Rico, Italy, Belgium, Mexico, Switzerland, Portugal, Netherlands, United Kingdom
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

HIV Infection

United States, Australia, France, United Kingdom, Belgium, Germany, Spain, Argentina, Chile, Mexico, Portugal, Malaysia, Panama, South Africa, Canada, Netherlands, Brazil, Puerto Rico, Austria, Russian Federation, Thailand, Hungary, Denmar... and more
GlaxoSmithKline

Completed

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

HIV Infection

United States
Tibotec Pharmaceuticals, Ireland

Approved for marketing

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

HIV Infections

United States, Belgium, Germany, Taiwan, Spain, Switzerland, Mexico, Slovenia, Malaysia, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Russian Federation, Czech Republic, Puerto Rico, Thailand, Hungary, Luxembourg, Venezuela
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

HIV Infections

United States, Germany, Spain, Taiwan, United Kingdom, Canada, Belgium, France, Italy, South Africa, Argentina, Russian Federation, Denmark, Mexico, China, Sweden, Brazil
ViiV Healthcare

Terminated

GW873140 In Combination With Combivir In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
Bristol-Myers Squibb

No longer available

Atazanavir for HIV Infected Individuals: An Early Access Program

HIV Infections

United States, Puerto Rico
Gilead Sciences

Completed

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

HIV | Human Immunodeficiency Virus | HIV-1

United States, Puerto Rico
Boehringer Ingelheim

Completed

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

HIV Infections

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Italy, Mexico, Netherlands, Portugal, Spain, Switzerland, United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (FLAMINGO)

Infection, Human Immunodeficiency Virus

Spain, France, Germany, United States, Italy, Romania, Russian Federation, Switzerland, Puerto Rico
ViiV Healthcare

Active, not recruiting

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

HIV Infections

United States, Spain, France, Australia, Germany, Belgium, Canada, Argentina, Brazil, Italy, Romania, Mexico, Taiwan, Netherlands, South Africa, Russian Federation, Greece, Portugal, United Kingdom, Poland, Peru, Chile, Colombia, Ireland and more
Genzyme, a Sanofi Company

Completed

Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency (ASCEND)

Sphingomyelin Lipidosis

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Chile, France, Germany, Italy, Japan, Netherlands, Portugal, Spain, Tunisia, Turkey, United Kingdom
ViiV Healthcare

Active, not recruiting

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF (EYEWITNESS)

HIV Infections | HIV

Netherlands, Germany, Mexico, Spain, United States, Belgium, Portugal, Canada, United Kingdom, Italy, Austria, France
Gilead Sciences

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER)

Pre-Exposure Prophylaxis of HIV-1 Infection

United States, Austria, Denmark, United Kingdom, Netherlands, Italy, Germany, Canada, Ireland, France, Spain
National Institute of Allergy and Infectious Diseases...
Lederle Laboratories; Hoechst Marion Roussel

Completed

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

HIV Infections | Tuberculosis

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth

HIV Infections | Dyslipidemia | Osteoporosis | Osteopenia | Lipodystrophy | HIV-Associated Lipodystrophy Syndrome | HIV Lipodystrophy Syndrome

United States, Puerto Rico
Boehringer Ingelheim

Approved for marketing

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

HIV Infections

United States, Australia, Belgium, Denmark, France, Greece, Ireland, Italy, Portugal, South Africa, Switzerland, United Kingdom
ViiV Healthcare

Terminated

GW873140 In Combination With Kaletra In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Germany, France, Canada, Spain, Italy, Portugal, United Kingdom, Denmark, Netherlands
Gilead Sciences

Active, not recruiting

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PURPOSE 2)

Pre-Exposure Prophylaxis of HIV Infection

United States, Thailand, Brazil, Peru, Argentina, South Africa, Mexico, Puerto Rico
GlaxoSmithKline

Completed

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

HIV Infection | Infection, Human Immunodeficiency Virus

United States, Belgium, France, Germany, Spain, Canada, Italy, Portugal, Romania, Austria, Switzerland, Poland, Latvia, Luxembourg
National Institute of Allergy and Infectious Diseases...
Jacobus Pharmaceutical

Completed

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

HIV Infections | Pneumonia, Pneumocystis Carinii

United States, Puerto Rico
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Canada, Portugal, Italy, Belgium
ViiV Healthcare

Terminated

A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

United States, France, Germany, Canada, Italy, Australia, Belgium, Portugal, Puerto Rico, Romania, United Kingdom
Janssen R&D Ireland

Completed

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Hepatitis C Virus Genotype-1

United States, France, United Kingdom, Germany, Spain, Portugal, Canada, Puerto Rico

Clinical Trials on Vitamin D Deficiency Disease in Korea, Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations